Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow. They include numerous forms of leukemia, lymphoma and myeloma. Symptoms of blood cancer are tested by specialist called hematologist. There is high scope for the Hematological Cancers Market with increasing cases of different types of blood cancers across the globe through 2022.
Scope of the Hematological Cancers Market:
The Hematological Cancers Market is forecast to rise from a value of $30.7 billion in 2015 to $70.1 billion in 2022, at a CAGR of 12.5%. Over the past 15 years, the treatment of hematological malignancies has changed significantly, with the development of targeted therapies.
In the Hematological Cancers Market, these developments were based on the growing understanding of the signaling pathways involved in disease pathogenesis. Notable examples include the approval of rituximab in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin’s lymphoma.
In the Hematological Cancers Market, the hematological cancer has more active pipeline products than the respiratory and cardiovascular therapy areas, which indicates how active this disease cluster is in terms of product development. The Hematological cancers clinical trials have an overall attrition rate of 70.3%.
Overall, there are 1,207 products in active development in the hematological cancer therapy area. The indications included in this disease cluster are classified under oncology, which is the largest therapy area in terms of pipeline products, consisting of 6,936 drugs in development in the Hematological Cancers Market.
Complete research on Hematological Cancers Market available at http://www.marketintelreports.com/report/gbihc407mr/global-hematological-cancers-market-to-2022–commercially-successful-targeted-therapies-and-large-innovative-pipeline-to-drive-market
Segmentation and key players of the Hematological Cancers Market:
The Hematological Cancers Market is segmented into various categories by type, by treatment, by marketed products, by pipeline, by clinical trials, revenue forecast by molecular target, by assessment of key pipeline products and by geography.
By type: Leukemia, Lymphoma and Myeloma
By treatment: Surgery and Radiation Therapy, Stem Cell Transplantation and Pharmacological Therapies
By marketed products: Rituxan/Mabthera (rituximab) – Roche, Gleevec/Glivec (Imatinib) – Novartis, Revlimid (lenalidomide) – Celgene, Velcade (bortezomib) – Millennium/Takeda/Johnson & Johnson, Sprycel (dasatinib) – Bristol-Myers Squibb/Otsuka Pharmaceutical, Tasigna (nilotinib) – Novartis, Pomalyst (pomalidomide) – Celgene, Vidaza (azacitidine) – Celgene, Kyprolis (carfilzomib) – Onyx/Amgen, Adcetris (brentuximab vedotin) – Seattle Genetics/Millennium and Imbruvica (ibrutinib) – AbbVie/Johnson & Johnson
By pipeline: pipeline products by stage of development and molecule type, pipeline products by molecular target
By clinical trials: clinical trial failure rates, clinical trial duration, clinical trial size and cumulative clinical trial size
Revenue forecast by molecular target: Cancer Immunotherapies/Tumor-Associated Antigen, Signal Transduction and Receptor Tyrosine Kinases and Ligands
By assessment of key pipeline products: Venetoclax (ABT-199) – AbbVie/Roche, KTE-C19 – Kite Pharma, Selinexor (KPT-330) – Karyopharm Therapeutics, Polatuzumab Vedotin (RG-7596) – Roche, Tisagenlecleucel-T (CTL-019) – Novartis and Midostaurin (PKC-412) – Novartis
By geography: North America, South America, Europe, Asia Pacific and ROW
Order a copy of Hematological Cancers Market report @ http://www.marketintelreports.com/purchase.php?id=gbihc407mr
The key players in the Hematological Cancers Market are as follows:
- Johnson & Johnson
- Karyopharm Therapeutics
The Hematological Cancers Market is a high potential market with many countries and medical corporations heavily investing in R&D for treatment and drug development. This market is expected to witness high growth owing to the increasing cases of hematological cancers in the global population through 2022.
Check research sample here http://www.marketintelreports.com/pdfdownload.php?id=gbihc407mr
On a related note, another research on
Global Non-Hematological Cancers Market to 2021 – Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics @ http://www.marketintelreports.com/report/gbihc405mr/global-nonhematological-cancers-market-to-2021–strong-growth-driven-by-increased-uptake-of-low-toxicity-targeted-treatments-and-versatile-biologics
MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.
MarketIntelReports currently has more than 10,000 plus titles and 35+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.
Company Name: MarketIntelReports
Contact Person: Mayur S.
Email: Send Email
Address:2711 Centerville Road, Suite 400
Country: United States